Company
Nyxoah SA
Headquarters: Mont-Saint-Guibert, Belgium
Employees: 71
CEO: Mr. Olivier Taelman
Market Cap
$295.2 Million
USD as of July 1, 2025
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $193.76 B |
| EssilorLuxottica SA | $128.90 B |
| Becton, Dickinson and Company | $50.81 B |
| Alcon Inc. | $44.33 B |
| HOYA Corp | $40.30 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Stocks & Indices
Nyxoah SA has the following listings and related stock indices.
Stock: NASDAQ: NYXH wb_incandescent
Stock: FSX: 5YI wb_incandescent